Login to Your Account

Pharma: Clinic Roundup

Friday, September 27, 2013

• Eli Lilly and Co., of Indianapolis, disclosed positive patient-reported health outcomes from a Phase III trial of dulaglutide, an investigational, long-acting glucagon-like peptide 1 receptor agonist being studied as a once-weekly treatment for Type II diabetes.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription